- Enoximone
-
- $33.00 / 1mg
-
2024-10-31
- CAS:77671-31-9
- Min. Order:
- Purity: 95.52%
- Supply Ability: 10g
- Enoximone
-
- $1.00 / 1g
-
2024-10-22
- CAS:77671-31-9
- Min. Order: 1g
- Purity: 85.0-99.8%
- Supply Ability: 20tons
|
| Enoximone Basic information |
Product Name: | Enoximone | Synonyms: | ENOXIMONE;2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-;Fenoximone;MDL-17043;Pedane;Perfan;RMI-17043;4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one | CAS: | 77671-31-9 | MF: | C12H12N2O2S | MW: | 248.3 | EINECS: | | Product Categories: | APIs;API | Mol File: | 77671-31-9.mol | |
| Enoximone Chemical Properties |
Melting point | 255-258°C | density | 1.33 | storage temp. | Sealed in dry,Room Temperature | solubility | DMSO: 28 mg/mL, soluble | pka | 10.37±0.70(Predicted) | form | solid | color | light yellow | CAS DataBase Reference | 77671-31-9(CAS DataBase Reference) |
RIDADR | 3249 | WGK Germany | 3 | HazardClass | 6.1(b) | PackingGroup | III |
| Enoximone Usage And Synthesis |
Description | Enoximone is a phosphodiesterase inhibitor indicated for selective use as a
cardiostimulant in heart transplant patient maintenance. It is currently being investigated
for other indications including acute congestive heart failure. | Originator | Merrell Dow (USA) | Uses | Enoximone is a phosphodiesterase inhibitor used in the treatment of congestive heart failure and is selective to phosphodiesterase 3. Potent PDE-3 inhibitor. | Definition | ChEBI: Enoximone is an aromatic ketone. | Brand name | Perfan IV | Biological Activity | Inhibitor of type III phosphodiesterase (PDE3). Increases intracellular cyclic AMP (cAMP) concentrations and enhances myocardial contractility. Also induces concentration-dependent vasodilation in vitro . | Biochem/physiol Actions | Selective phosphodiesterase III (PDE3) inhibitor. Prevents the degradation of cAMP by PDE. Increased cAMP results in enhanced contractility of the heart. | storage | Store at +4°C |
| Enoximone Preparation Products And Raw materials |
|